Home › Trial NCT05394415
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
- Trial IDNCT05394415
- StatusUnknown
- PhasePhase 1/2
- Study typeInterventional
- SponsorJiangsu Cancer Institute & Hospital
- Enrollment30
- Start date2022-05-01
- ConditionsEsophageal Squamous Cell Carcinoma · Tislelizumab · Chemoradiation
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.